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Objectives This paper describes the medical therapy used in the COURAGE (Clinical Outcomes Utilizing Revascularization
and Aggressive Drug Evaluation) trial and its effect on risk factors.
Background Most cardiovascular clinical trials test a single intervention. The COURAGE trial tested multiple lifestyle and phar-
macologic interventions (optimal medical therapy) with or without percutaneous coronary intervention in pa-
tients with stable coronary disease.
Methods All patients, regardless of treatment assignment, received equivalent lifestyle and pharmacologic interventions for
secondary prevention. Most medications were provided at no cost. Therapy was administered by nurse case manag-
ers according to protocols designed to achieve predefined lifestyle and risk factor goals.
Results The patients (n  2,287) were followed for 4.6 years. There were no significant differences between treatment
groups in proportion of patients achieving therapeutic goals. The proportion of smokers decreased from 23% to
19% (p  0.025), those who reported 7% of calories from saturated fat increased from 46% to 80% (p 
0.001), and those who walked 150 min/week increased from 58% to 66% (p  0.001). Body mass index in-
creased from 28.8  0.13 kg/m2 to 29.3  0.23 kg/m2 (p  0.001). Appropriate medication use increased
from pre-randomization to 5 years as follows: antiplatelets 87% to 96%; beta-blockers 69% to 85%; renin-
angiotensin-aldosterone system inhibitors 46% to 72%; and statins 64% to 93%. Systolic blood pressure de-
creased from a median of 131  0.49 mm Hg to 123  0.88 mm Hg. Low-density lipoprotein cholesterol de-
creased from a median of 101  0.83 mg/dl to 72  0.88 mg/dl.
Conclusions Secondary prevention was applied equally and intensively to both treatment groups in the COURAGE trial by nurse
case managers with treatment protocols and resulted in significant improvement in risk factors. Optimal medical
therapy in the COURAGE trial provides an effective model for secondary prevention among patients with chronic
coronary disease. (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation; NCT00007657)
(J Am Coll Cardiol 2010;55:1348–58) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.10.062Care System–Audie Murphy Campus, San Antonio, Texas; §Veterans Affairs (VA)rom the *Departments of Medicine and Emergency Medicine, Vanderbilt University
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March 30, 2010:1348–58 Optimal Medical Therapy in the COURAGE Trialumerous large randomized clinical trials have demon-
trated the efficacy of secondary prevention of coronary
rtery disease (CAD). Effective lifestyle interventions in-
lude smoking cessation (1), dietary intervention (2,3), and
xercise (4,5). Effective pharmacologic interventions include
spirin (6), clopidogrel (6), beta-blockers (7,8), angiotensin
onverting enzyme inhibitors (9,10), and statins (11). Stud-
es of control of blood pressure (12), low-density lipoprotein
LDL) cholesterol (11,13–16), and—less consistently—
lood glucose (17–19) serve as the basis for current second-
ry prevention guidelines. Although most secondary pre-
ention trials have tested the impact of a single risk factor
See page 1359
ntervention, the American College of Cardiology (ACC),
he American Heart Association (AHA), and the Canadian
ardiovascular Society recommend comprehensive lifestyle
nd pharmacologic interventions with specific risk factor
argets (20–22). Few clinical trials have included multiple
isk factor intervention with behavioral and pharmacologic
herapy as recommended by practice guidelines (23,24).
Previous randomized trials that compared percutaneous
oronary intervention (PCI) with medical therapy in pa-
ients with stable CAD failed to apply medical therapy that
as multifaceted, aggressive, and provided equally to both
reatment arms (25). The COURAGE (Clinical Outcomes
tilizing Revascularization and Aggressive Drug Evalua-
ion) trial tested the impact of comprehensive intensive
ifestyle and pharmacologic interventions (optimal medical
herapy [OMT]) with or without PCI in 2,287 patients
ith stable CAD. There was no difference in the primary
utcome of death or myocardial infarction (MI) during 4.6
ears of follow-up (26), and the PCI group had a small but
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D
lignificant incremental benefit in
ngina control that disappeared
y 36 months (27). This report
nalyzes the completeness and
uccess of medical therapy in the
OURAGE trial.
ethods
he methods, patient eligibility cri-
eria, baseline characteristics, and
ain results of the COURAGE
rial have been described previ-
usly (26,28). Data management
nd analyses were performed solely
y the data coordinating center
ith oversight of the trial executive
ommittee, which had full access to the data and analyses and
ouches for their accuracy and completeness. Patients were
nrolled from June 1999 to January 2004, and the study closed
n June 30, 2006.
reatment. RISK FACTOR GOALS. Risk factor goals were
ased on the 1995 ACC/AHA secondary prevention guide-
ines (Table 1) (29), although the blood pressure and LDL
holesterol goals were more aggressive in anticipation of
hat might become practice guidelines by the end of the
rial. The LDL cholesterol goal—60 to 85 mg/dl—was
stablished by the steering committee in 1997 when the
ational Cholesterol Education Program goal for CAD
atients was 100 mg/dl. In July 2004, the National
holesterol Education Program established an optional
DL cholesterol goal of 70 mg/dl for “very high risk
atients” (30), and the COURAGE steering committee
dopted that goal for the remainder of the trial.
isk Factor Goals in the COURAGE TrialTable 1 Risk Factor Goals in the COURAGE Trial
Risk Factor Goal
Smoking Cessation
Total dietary fat/saturated fat 30%/7% of calories
Dietary cholesterol 200 mg/day
Physical activity 30–45 min, moderate intensity 5 times/week
Body weight by BMI Initial BMI Weight Loss Goal
25–27.5 kg/m2 BMI 25 kg/m2
27.5 kg/m2 10% relative weight loss
Blood pressure 130/85 mm Hg (130/80 mm Hg if
diabetes or renal disease present)
LDL cholesterol (primary goal) 60–85 mg/dl; the goal became70 mg/dl in
July 2004
HDL cholesterol (secondary goal) 40 mg/dl
Triglyceride (secondary goal) 150 mg/dl
Diabetes HbA1c 7.0%
MI body mass index; COURAGE Clinical Outcomes Utilizing Revascularization and Aggressive
Abbreviations
and Acronyms
ACC  American College of
Cardiology
AHA  American Heart
Association
CAD  coronary artery
disease
HbA1c  hemoglobin A1c
LDL  low-density
lipoprotein
MI  myocardial infarction
OMT  optimal medical
therapy
PCI  percutaneous
coronary interventionrug Evaluation; HbA1c  hemoglobin A1c; HDL  high
ipoprotein.-density lipoprotein; LDL  low-density
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Optimal Medical Therapy in the COURAGE Trial March 30, 2010:1348–58ASE MANAGEMENT AND LIFESTYLE INTERVENTIONS.
ach patient met with a nurse case manager at baseline and
, 2, 3, and 6 months, then every 6 months until the study
nded. At each visit lifestyle and medication adherence were
ssessed, and body weight, blood pressure, fasting glucose,
nd lipid values were measured. Lipids were analyzed in a
ore laboratory; glucose and hemoglobin A1c (HbA1c) were
nalyzed locally. Diabetes was defined as having a history of
iabetes or taking hypoglycemic medication at baseline. The
bA1c was collected at baseline in most patients but during
ollow-up only in patients defined as having diabetes at
aseline.
Lifestyle intervention was delivered equally to both treat-
ent groups at each visit. Case managers were trained
efore trial launch and at annual meetings to assess patient
ehaviors and provide behavioral counseling focused on
moking cessation, nutrition, physical activity, and weight
anagement. Each patient’s readiness to change health-
elated behaviors was assessed with a system developed by
he Patient-centered Assessment and Counseling for Exer-
ise and nutrition (PACE) project (31). Lifestyle counseling
as standardized across sites with written materials devel-
ped by the PACE project, including scripts to instruct
atients regarding lifestyle change (32). These materials
ere designed for brief, practical, focused interventions by a
hysician or nurse in an outpatient setting. A more detailed
escription of the lifestyle intervention and training for
urse case managers is provided in the Online Appendix.
The behavioral counseling was based on Social Cognitive
heory (33) and the Transtheoretical Model (34). For each
ehavioral risk factor, patients were categorized into pre-
ontemplators (those who do not wish to change), contem-
lators (those who are willing to change), and actives (those
Pharmacologic Therapy in the COURAGE TrialTable 2 Pharmacologic Therapy in the COUR
Medication Class Drug
Antiplatelet agents Aspirin (clopidogrel if aspir
tolerated)
ACE inhibitors Lisinopril
Angiotensin receptor blocker Losartan
Beta-blocker Long-acting metoprolol
Thiazide diuretic Any
Statin Simvastatin
Calcium antagonist Amlodipine
Long-acting nitrate Isosorbide mononitrate
Niacin extended-release niacin
Cholesterol absorption
inhibitor
Ezetimibe
Fibrate Fenofibrate
Omega-3 fatty acids Various formulations
ACE  angiotensin converting enzyme; LVEF  left ventricular ejection
as in Table 1.ho are already meeting the recommended goal). Nurse tase managers were trained to provide messages tailored to
he patient’s stage of change for each behavioral risk factor.
ach stage-based message focused on known mediators of
ehavior change (e.g., goal setting, increasing social support,
nd self-efficacy). Print-based patient materials were used to
ssess and counsel patients (see examples in the Online
ppendix).
Smokers who were pre-contemplators were given advice and
ationale to quit. Smokers who were contemplators were
rovided with stage-based counseling, pharmacologic therapy,
nd/or referral to a formal smoking cessation program.
Diet was assessed with MEDFICTS, a questionnaire
ecommended by the National Cholesterol Education Pro-
ram to assess dietary fat (35,36). The questionnaire can be
elf-administered in 3 to 5 min and scored by a health care
rovider in 2 min. Nutritional counseling was designed to
chieve the dietary guidelines of the National Cholesterol
ducation Program (35,37). With the same stage-based
pproach, patients were advised to reduce calories, total fat,
nd saturated fat and increase consumption of fruits and
egetables.
Subjects were counseled to gradually increase moderate-
ntensity physical activity to 30 to 45 min 5 times/week.
ypically this was moderate-intensity walking. Counseling
as tailored for weight loss if needed.
HARMACOLOGIC THERAPY. Pharmacologic therapy con-
ormed with ACC/AHA guidelines for secondary preven-
ion and management of angina (20,21). All patients re-
eived the same medical therapy for secondary prevention,
egardless of treatment assignment (Table 2). The intensity
f anti-anginal therapy varied according to angina severity.
atients received medications at no cost except for aspirin,
Trial
Indications
Aspirin for all subjects; clopidogrel for at least 1 month
after PCI with bare-metal stent
Hypertension, heart failure, LVEF 40%; encouraged
for all patients
Consider in individuals with hypertension or clinical
evidence of heart failure or LVEF 40% who are
intolerant of ACE inhibitors
Hypertension/angina/post-MI
Hypertension
All subjects
Hypertension/angina
Angina
LDL 85 mg/dl, HDL 40 mg/dl, TG 150 mg/dl on
statin
LDL 85 mg/dl on statin
TG 150 mg/dl on statin
TG 150 mg/dl on statin
n; MI myocardial infarction; TG  triglycerides; other abbreviationsAGE
in nothiazide diuretics, fenofibrate, and omega-3 fatty acids.
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March 30, 2010:1348–58 Optimal Medical Therapy in the COURAGE TrialAmong patients randomized to PCI with no history of
I, an attempt was made to discontinue long-acting
etoprolol, amlodipine, and/or isosorbide mononitrate if
hey had no angina 3 to 6 months after PCI. Patients
ndergoing PCI received aspirin and clopidogrel according
o prevailing treatment guidelines (38). If a patient was not
t blood pressure or lipid goals, pharmacologic therapy was
djusted according to study protocols (see treatment algo-
ithms in the Online Appendix).
For LDL cholesterol control, all patients were prescribed
imvastatin according to a dosing algorithm. If simvastatin
as not tolerated or was not effective, patients were free to
se other statins. Extended-release niacin or ezetimibe was
dded if needed to reach goal. After the LDL cholesterol
oal was achieved, an attempt was made to raise high-
ensity lipoprotein cholesterol above 40 mg/dl and lower
riglycerides below 150 mg/dl with lifestyle change,
xtended-release niacin, fibrates, or omega-3 fatty acids.
DHERENCE TO MEDICATIONS. Adherence to medical
herapy was assessed by the 4-item self-report scale devel-
ped by Morisky et al. (39). Scores range from 0 to 4; higher
cores indicate worse adherence. A score of 0 to 1 was
efined as adherent.
ATIENT SATISFACTION. We assessed patient satisfaction
t baseline and 1, 3, 6, and 12 months and annually
hereafter with the Seattle Angina Questionnaire Treatment
atisfaction scale, which ranges from 0 to 100 (40). Higher
cores indicate greater patient satisfaction with therapy.
tatistical analysis. The data are presented as percentage
f individuals in each treatment group. Continuous vari-
bles are described as median  standard error of the
edian (41). Missing data were not included in the calcu-
ation of medians or percentages. For comparisons between
alues at baseline and 5 years, McNemar’s test was used for
iscrete variables, and Wilcoxon signed rank test was used
or continuous variables (lifestyle changes, therapeutic tar-
ets). Proportions of patients taking various medications
ssigned to the PCI group compared with the OMT group
re compared at each visit with the chi-square test (phar-
acologic therapy). Comparisons of continuous variables
etween treatment groups at each visit were made with the
edian test (therapeutic targets). For over-time compari-
ons between treatments, sequential differences were mod-
led with baseline, interval, time, and (time)2 in addition to
reatment (therapeutic targets, treatment satisfaction). The
ntention-to-treat principle was used in all analyses.
esults
aseline characteristics. Baseline characteristics were sim-
lar between groups (Table 3).
ifestyle change. In aggregate (both treatment groups
ombined), smoking decreased from 23% to 19% (p 
.025). The proportion of subjects who reported the dietary
oal of 7% of calories from saturated fat increased from t6% to 80% (p  0.001). The proportion of subjects who
chieved the physical activity goal in the form of walking
150 min/week increased from 58% to 66% (p  0.001).
hen analyzed by treatment group, there were no signifi-
ant differences between groups at any time for any lifestyle
ariables (Fig. 1). Body mass index increased from 28.8 
.13 kg/m2 at baseline to 29.3 0.23 kg/m2 at 5 years (p
.001).
harmacologic therapy, persistence, and adherence.
igure 2 shows medication use during the trial. In aggre-
ate, medication use increased from baseline to 5 years as
ollows: antiplatelets 87% to 96%; beta-blockers 69% to
5%; and renin-angiotensin-aldosterone system inhibitors
6% to 72%. Before randomization, 31% of patients took
alcium channel blockers. By 6 months, 40% of the PCI
roup and 50% of the OMT group took these agents
p  0.001), and this difference persisted though 5 years of
ollow-up (42% vs. 52%, respectively, p  0.004). Before
andomization, 58% took long-acting nitrates. By 6 months,
5% of the PCI group and 71% of the OMT group took
aseline Clinical and Demographic CharacteristicsTable 3 Baseline Clinical and Demographic Characteristics
Characteristic
PCI  OMT
(n  1,149)
OMT
(n  1,138) p Value
Age, yrs (mean  SD)* 61.5 10.1 61.8 9.7 0.54
Sex†
Male 979 (85) 968 (85) 0.95
Female 169 (15) 169 (15)
Race or ethnic group†
White 988 (86) 975 (86) 0.64
Black 57 (5) 57 (5)
Hispanic 68 (6) 58 (5)
Other 35 (3) 47 (4)
History†
Diabetes 367 (32) 399 (35) 0.12
Hypertension 757 (66) 764 (67) 0.53
Congestive heart failure 57 (5) 51 (5) 0.59
Cerebrovascular disease 100 (9) 102 (9) 0.83
Myocardial infarction 437 (38) 439 (39) 0.80
Prior PCI 174 (15) 185 (16) 0.49
CABG 124 (11) 124 (11) 0.94
Risk factors‡
Systolic blood pressure (mm Hg) 131 0.77 130 0.66 0.36
Diastolic blood pressure (mm Hg) 74 0.33 74 0.33 0.94
Total cholesterol (mg/dl) 172 1.37 177 1.41 0.01
HDL cholesterol (mg/dl) 39 39 39 0.37 0.97
LDL cholesterol (mg/dl) 100 1.17 102 1.22 0.18
TG (mg/dl) 143 2.96 149 3.03 0.12
BMI (kg/m2) 28.7 0.18 28.9 0.17 0.51
HbAlc in diabetic subjects (%)‡ 6.9 0.1 7.1 0.1 0.18
Current smoker† 260 (23) 259 (23) 0.89
AHA Step 2 diet† 626 (55) 613 (54) 0.54
Moderate activity†§ 290 (25) 279 (25) 0.72
Variables were compared with the t test. †Variables were compared with the chi-square or
ilcoxon rank sum test, n (%). ‡Variables were compared with the median test (median SE). §At
east 30 to 45 min of moderate activity 5 times/week or vigorous activity 3 times/week.
AHA  American Heart Association; CABG  coronary artery bypass graft surgery; other
bbreviations as in Tables 1 and 2.hese agents (p  0.001); at 5 years, the proportions were
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Optimal Medical Therapy in the COURAGE Trial March 30, 2010:1348–580% versus 57%, respectively (p  0.001). Statin use rose
rom 64% to 93%, niacin use rose from 1% to 18%, and
zetimibe use rose from 0% to 33% (at the trial onset,
zetimibe was not approved for use). The use of any lipid
edication rose from 67% to 97%.
At baseline, 51% of PCI group and 51% of OMT group
atients took the combination of aspirin, beta-blocker, and
ipid drug therapy. By 5 years, the proportions rose to 79%
nd 80%, respectively. At baseline, 27% of PCI group and
9% of OMT group patients took aspirin, beta-blocker,
ipid lowering, and renin-angiotensin-aldosterone system
nhibitor therapy. By 5 years, the proportions were 55% and
1%, respectively. No between-group differences were sta-
istically significant.
At 6 months, average self-reported adherence to pre-
cribed medications was 97% in both groups; adherence
emained at 95% throughout the trial, with no significant
ifference between groups.
iabetes and metabolic syndrome. At baseline, 845 pa-
ients (37%) without the diagnosis of diabetes had fasting
lucose 100 mg/dl, 635 (28%) had impaired fasting
lucose (fasting glucose 100 to 125 mg/dl), and 766 (34%)
Figure 1 Lifestyle and Weight Variables During the Trial
A MEDFICTS score 40 indicates 7% of calories from saturated fat. There were
time. The chi-square test was used to compare smoking at each time point, and t
mal medical therapy; PCI  percutaneous coronary intervention.ad diabetes. During the study, 191 patients developed iiabetes, 97 in the PCI group and 94 in the OMT group.
t baseline, 59% of patients had metabolic syndrome.
herapeutic targets achieved. Figure 3 presents the
hanges in blood pressure, lipids, and HbA1c. Median
ystolic blood pressure was 131  0.49 mm Hg at study
ntry and 123 0.88 mm Hg at 5 years (p 0.001). Before
andomization, median LDL cholesterol was 101  0.83
g/dl. At 6 months the median LDL cholesterol was
2  0.62 mg/dl and declined to 72  0.88 mg/dl at 5
ears (p  0.001). There were no significant intergroup
ifferences in LDL cholesterol levels at any visit during
he study. During the trial high-density lipoprotein cho-
esterol rose from 39  0.3 mg/dl to 41  0.5 mg/dl
p  0.001) and triglycerides fell from 146  2 mg/dl to
26  3 mg/dl (p  0.001). Among patients with
iabetes, HbA1c was 7.0  0.1% at baseline and 7.1 
.01% at 5 years (p  1.0).
Figure 4 shows the percentage of subjects who achieved
lood pressure, lipid, and HbA1c goals. At randomization,
3% of patients were at the systolic blood pressure goal of
130 mm Hg; this increased to approximately 60% by 3
ears and remained unchanged through the rest of the trial
nificant differences between treatment groups for any of the comparisons at any
dian test was used for the other variables. BMI  body mass index; OMT  opti-no sig
he men both groups. At randomization, 28% of patients had
1353JACC Vol. 55, No. 13, 2010 Maron et al.
March 30, 2010:1348–58 Optimal Medical Therapy in the COURAGE TrialFigure 2 Percent of Patients Taking Medications During the Trial
Before randomization medications were not collected on the first 432 patients who enrolled. With McNemar’s test, p  0.001 for all drug classes comparing baseline
and 5 years except calcium channel blockers (p  0.01). With the chi-square test there is no difference between treatment groups at any follow-up visit for any drug
classes except nitrates (p  0.001 for all visits) and calcium channel blockers (p  0.001 until 3 years when p  0.005, 4 years p  0.06, and 5 years p  0.004).
ACE  angiotensin-converting enzyme; ARB  angiotensin-receptor blocker; other abbreviations as in Figure 1.
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Optimal Medical Therapy in the COURAGE Trial March 30, 2010:1348–58DL cholesterol levels at study goal (85 mg/dl); by 5
ears, this proportion had increased to 70%. With the more
ggressive LDL cholesterol target of 70 mg/dl proposed
n 2004 (30), 14% of patients were below this target at
andomization, and 46% achieved this target by 5 years.
atient adherence and risk factor control. During the first
ear, 4% of patients in each treatment group missed follow-up
isits; during subsequent years, the proportion of patients who
issed clinic visits gradually increased. By year 5, 12% of the
Figure 3 Changes in Risk Factors During the Trial
There was no significant treatment effect for any of the variables over the course
bin A1c (HbA1c; glycated hemoglobin) is reported only for those patients with diab
abbreviations as in Figure 1.CI group and 10% of the OMT group had missed at least 1 tisit during the trial (see the Online Appendix). Patients who
ttended every visit had better systolic blood pressure and LDL
holesterol-lowering than patients who missed visits (see Figs.
and B in the Online Appendix). There were no significant
ifferences between treatment groups. Medication-adherent
atients had lower systolic blood pressure and LDL cholesterol
han patients who were not adherent (see Figs. C and D in the
nline Appendix).
reatment satisfaction score. The Seattle Angina Ques-
trial with the modeling procedure described in the statistical methods. Hemoglo-
t baseline. HDL  high-density lipoprotein; LDL  low-density lipoprotein; otherof the
etes aionnaire Treatment Satisfaction score was 88 for the PCI
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March 30, 2010:1348–58 Optimal Medical Therapy in the COURAGE Trialroup and 86 for the OMT group at randomization. The
cores gradually increased during the study, and at 5 years, they
ere 92 (p 0.08) and 94 (p 0.001), respectively, indicating
hat patients were satisfied with their treatment and their
atisfaction increased during the trial. There were no differ-
nces between treatment groups over time (p  0.91).
iscussion
nlike previous trials of revascularization versus medical
herapy, the COURAGE trial applied a multifaceted strat-
gy of intensive secondary prevention to both treatment
rms. We succeeded in achieving multiple therapeutic
Figure 4 Percent of Patients at Target During the Trial
The HbA1c is reported only for those patients with diabetes at baseline. With t
6 months (p  0.03), 1 year (p  0.01), and 2 years (p  0.003) and at LDL
groups for any other comparisons at any time. *Blood pressure target was 1
Figures 1 and 3.argets and in applying OMT equally to both treatment aroups. Moreover, this aggressive treatment strategy was
ssociated with improved treatment satisfaction. Smoking,
ietary fat intake, and physical activity improved. Although
ome behavioral improvements were modest, they were
bserved over several years and achieved with simple coun-
eling techniques that can be replicated. We were not
uccessful in assisting people with weight loss.
Self-reported long-term adherence to drug therapy and
isk factor control in the COURAGE trial far exceeded
hat has been reported in surveys of CAD outpatients. The
UROASPIRE II (European Action on Secondary and
rimary Prevention by Intervention to Reduce Events) trial,
i-square test, significantly more OMT patients were at blood pressure goal at
t 1 year (p  0.04). There were no significant differences between treatment
mm Hg if diabetes or renal disease was present. Abbreviations as inhe ch
goal a
30/80European survey of CAD patients, found use of aspirin to
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ipid-lowering therapy to be 61% (42). Newby et al. (43)
eported consistent use of aspirin to be 71%, use of beta-
lockers to be 46%, use of lipid-lowering therapy to be 44%,
nd use of the combination of aspirin, beta-blockers, and
ipid-lowering therapy to be 21%. The corresponding num-
ers at the end of the COURAGE trial were substantially
igher: aspirin, 96%; beta-blockers, 85%; lipid-lowering
herapy, 97%; and all 3 drug classes, 80%. Our success might
e attributable to several factors. First, clinical trial volun-
eers are more likely to adhere to drug regimens. Second,
rugs were provided free of charge. Third, treatment pro-
ocols were used to provide standardized care. Fourth,
urses who delivered the intervention were trained to
mprove lifestyle and medication adherence, shown previ-
usly to improve success in risk-factor control (23,44,45).
In the EUROASPIRE III trial, 18% of CAD patients
moked, 39% achieved blood pressure 140/90 mm Hg in
ondiabetic patients or 130/80 mm Hg in diabetic pa-
ients, and 54% attained total cholesterol 175 mg/dl (46).
y the end of the COURAGE trial, 19% of patients
moked, 61% achieved our more stringent blood pressure
oals, and 70% achieved our more aggressive lipid goal
LDL cholesterol 85 mg/dl). Hence, with the excep-
ions of smoking (where our positive effect was modest)
nd weight loss, we were quite successful in achieving and
aintaining ambitious risk-factor goals in high propor-
ions of patients. This endorses a secondary prevention
odel with nurse case managers with simple behavior
ssessment and counseling tools and treatment algo-
ithms to effect positive lifestyle change, appropriate use
f medications, and titration of medications to achieve
reatment targets. This method is consistent with guide-
ines from the ACC, AHA, and the Canadian Car-
iovascular Society (20,21) and is responsive to what
UROASPIRE investigators describe as “a compelling
eed for more effective lifestyle management of patients
ith coronary heart disease” (46).
tudy limitations. The design of the COURAGE trial
recludes the opportunity to measure the impact of OMT
n death, MI, or other major cardiovascular events,
ecause OMT was provided equally to both treatment
rms. With evidence from prior clinical trials, before the
nitiation of the COURAGE trial we projected a 3-year
rimary event rate of 16.4% in the PCI group and 21.0%
n the OMT group (relative difference of 22%, absolute
ifference of 4.6%). We observed a 4.6-year primary
vent rate of 19.0% in the PCI group and 18.5% in the
MT group (26). Hence, we overestimated the event
ate by a substantial margin. In part, this might have been
ue to the impact of OMT. The medical therapy deliv-
red in the COURAGE trial has been criticized as not
chievable in the real world (47). We cannot assess to
hat extent free medication influenced behavior, but we
cknowledge that medication adherence and persistence
ould probably have declined if patients had been re- fuired to share the cost of medications (48 –50). How-
ver, the key medications used in the COURAGE trial
re all available in more affordable generic forms. Fur-
hermore, OMT was delivered by nurses who were
rovided with simple protocols and a modest amount of
raining to deliver behavioral counseling. The frequency
f patient contact mandated by the protocol was within
he norms of conventional practice in the U.S. and
anada. Hence, this quality of care is feasible in typical
utpatient practice.
onclusions
edical therapy in the COURAGE trial was protocol-
riven, delivered by nurse case managers, comprehensive
n scope, intensive in its application, and provided equally
o patients whether or not they received PCI. Significant
ehavior change was achieved, self-reported medication
dherence and persistence was high, and therapeutic
argets were reached in large proportions of patients. The
elivery of OMT in the COURAGE trial is a model for
econdary prevention in practice, with potential policy
mplications regarding the use of nurse case managers and
ree medications to optimally manage patients with
hronic CAD.
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APPENDIX
or a detailed description of training for nurse case managers to perform
ifestyle assessment and behavioral counseling; samples of PACE materi-
ls; COURAGE treatment algorithms; and an analysis of clinic visit atten-
ance, medication adherence, and risk factor control, please see the
nline version of this article.
